AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013(placebo)
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04863053 — intervention group
Intervention type: OTHER
Intervention: Blood samples will be taken to assess platelet function. There is no change in treatment.
Study NCT02788812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP inguinal hernia repair
Description: Laparoscopic TAPP Hernioplasty
Study NCT02168101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.
Study NCT04498286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of SARS-CoV-2 antibodies
Description: Sars-CoV-2 RBD total antibody test developed by Sanquin
Study NCT01435694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lokomat (Hocoma, Switzerland)
Study NCT01435694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Study NCT03953677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 100 Mcg/mL Intravenous Solution
Description: Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
Study NCT03953677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose Infusion solution
Description: Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
Study NCT03689569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
Study NCT03689569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
Study NCT03689569 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Patients will be given 30 grams of corn starch
Study NCT02363777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
Study NCT02363777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral catheters
Description: Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
Study NCT04404673 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of urinary and sexual dysfunction after rectal resection
Description: Comparison among the 4 different surgical approaches for urinary and sexual function
Study NCT01845246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective TDM Arm of colistin
Study NCT02872870 — intervention group
Intervention type: BEHAVIORAL
Intervention: auditory lexical decision task
Study NCT02872870 — intervention group
Intervention type: DEVICE
Intervention: electroencephalogram
Study NCT01403779 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiotherapy (IMRT) for breast cancer
Description: right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
Study NCT04859348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy
Description: G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
Study NCT04859348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy and antenatal exercises
Description: G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
Study NCT02676674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Study NCT02676674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Study NCT03012191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
Study NCT01773967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGG
Description: LGG 10\^10 cfu PO BID X 5 days
Study NCT01773967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: micro-crystalline cellulose
Description: 1 capsule PO bid x 5 days
Study NCT04177615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboectomy
Description: Thromboectomy in Basilar Artery Occlusion patients
Study NCT02226588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT02226588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study NCT00847899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR9281
Description: AR9281 taken in BID dosing regimen for 28 days
Study NCT00847899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR9281
Description: AR9281 taken in TID dosing regimen for 28 days
Study NCT00847899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken in BID dosing regimen for 28 days
Study NCT00847899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken in TID dosing regimen for 28 days
Study NCT01109615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 400 mg/m2 on day 1 of a 3 weeks cycle
Study NCT01109615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
Study NCT03388801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
Study NCT03415425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Version of the Influenza Alert
Description: Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
Study NCT03415425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Modifications of the Influenza Alert
Description: Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
Study NCT01166789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 48ug daily taken as 24ug capsules twice per day, in morning and evening.
Study NCT01166789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily, taken in morning and evening
Study NCT02725450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery + Psychomotor Battery of fine motor skills
Description: Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
Study NCT02725450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Battery of fine motor skills Practice
Description: Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
Study NCT01481350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
Study NCT04981106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise
Description: The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared.
Study NCT02110849 — intervention group
Intervention type: RADIATION
Intervention: Proton
Description: Proton Therapy for Prostate Cancer
Study NCT02351739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab
Study NCT02351739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACP-196 in combination with pembrolizumab
Study NCT00609804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
Study NCT00609804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
Study NCT00609804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily by mouth
Study NCT04449276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT04449276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT03263741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + S-1 + Oxaliplatin
Description: Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
Study NCT04055467 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
Description: Brain imaging of alpha-7 nicotinic acetylcholine receptors
Study NCT04055467 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
Study NCT02040155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel nano-scintillator fiber-optic dosimeter (nanoFOD)
Description: This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
Study NCT03023241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
Study NCT04126603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
Study NCT04126603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo injection
Study NCT04029623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered Rhythmic Rehabilitation (PRR)
Description: Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
Study NCT02673099 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HDF online
Description: Hemodialysis by the HDF online method
Study NCT03279887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Study NCT03570242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study NCT05290506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
Study NCT04029623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group walking (WALK)
Description: WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
Study NCT02560480 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: to diagonose groin injury exactly in magnetic resonance imaging
Study NCT02061748 — intervention group
Intervention type: DRUG
Intervention: Observational
Description: Retrospective Chart Review
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Study NCT02989714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
Study NCT02989714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
Study NCT03035370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin PT 25 mcg
Description: Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Study NCT03035370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin PT 50 mcg
Description: Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
Study NCT03035370 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin PT Placebo
Description: Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
Study NCT01848067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01848067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given PO
Study NCT01848067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03398941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
Description: Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.